University of Cambridge: Investment Portfolio & Startup News
University of Cambridge
To add a bio or update investment portfolio click update information.
Investment Portfolio


52North raises £3.2m in funding led by Macmillan Cancer Support to support urgent cancer care diagnostics
52North is a medical technology spin-out from the University of Cambridge developing the Aster biomarker platform and Neutrocheck, a rapid finger-prick blood test. Neutrocheck supports remote triaging of chemotherapy patients at risk of neutropenic sepsis to reduce unnecessary emergency hospital visits.


T-Therapeutics secures £24m Series A extension with Tencent and BGF to develop T cell receptor therapeutics for cancer and autoimmune disease
T-Therapeutics develops next-generation T cell receptor therapies designed to target cancer and autoimmune disease, advancing bispecific molecules that selectively remove disease-driving immune cells while preserving healthy function.


NoBACZ Healthcare raises £4.8m led by The Yield Lab to expand liquid bandage technology for livestock and horses
NoBACZ Healthcare develops antibiotic-free liquid bandage technology for livestock and horses, creating protective wound coatings that reduce infection risk in agricultural environments.


Robin AI, leader in legal AI for business, confirms £20m further funding from customers and investors including Paypal Ventures
Robin AI develops legal AI software for large enterprises that analyses, summarises and extracts insights from complex contracts and documents, supporting due diligence, compliance and incident response at scale.
- 1(12 months)
- cam.ac.uk
More venture news
- 13 Nov 2026

JADEJADE secures £450k in funding led by GC Angels to help universities manage their international student recruitment agents
EquityHR - 10 Nov 2026

PlankyPlanky raises £6m in funding co-led by Innovation Global and Azimut to turn financial data into credit decisions
EquityFintech - 10 Nov 2026

AncepAncep raises £6m in funding led by Creandum to help insurance brokers cover the clients they’d normally turn down
EquityEnterprise